Application of a Physiologically Based Pharmacokinetic Approach to Predict Tenofovir Pharmacokinetics During Pregnancy

被引:0
作者
Abduljalil, Khaled [1 ]
Mendes, Mailys De Sousa [1 ]
Salem, Farzaneh [1 ,2 ]
Benaboud, Sihem [3 ,4 ]
Gardner, Iain [1 ]
机构
[1] Certara Predict Technol, Sheffield, England
[2] GlaxoSmithKline, Drug Metab & Pharmacokinet, Stevenage, England
[3] Univ Paris Cite, 1 U1343, Pharmacol & Evaluat Therapeut Chez Enfant & Femme, Inserm, Paris, France
[4] Grp Hosp Paris Ctr, Hop Europeen Georges Pompidou, Hop Cochin, AP HP,Serv Pharmacol Clin, Paris, France
关键词
amniotic fluid; fetal; pregnancy; placenta; PBPK; tenofovir; DRUG-DRUG INTERACTIONS; DISOPROXIL FUMARATE; POPULATION PHARMACOKINETICS; ANTIRETROVIRAL DRUGS; BIRTH OUTCOMES; IN-VITRO; EMTRICITABINE; WOMEN; COMBINATION; PARAMETERS;
D O I
10.1208/s12248-025-01031-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacotherapy during pregnancy requires a better understanding of the impact of changes in maternal physiology on the maternal and fetal drug exposure. The physiologically based pharmacokinetic (PBPK) modelling approach can be applied to predict maternal and fetal exposure. In vitro and in vivo PK data in non-pregnant individuals were compiled and used to develop and verify a PBPK model for tenofovir. The model was then used to predict the maternal and fetal tenofovir exposure during pregnancy, after incorporation of current knowledge on maternal and fetal physiological changes during pregnancy. Predicted concentrations and parameters from the PBPK model were compared to observed data. Predicted tenofovir PK agreed with observations in non-pregnant (13 studies) and pregnant (7 studies with differing gestational weeks) individuals. Observed concentrations fell within the PBPK 5th - 95th prediction intervals. Predicted PK parameters were within twofold of the reported parameters. The predicted tenofovir steady state cord-to-maternal exposure ratio at term was 0.85 (range: 0.62-0.98), which agrees with clinically observed ratios ranging between 0.60-1.00. A PBPK model for tenofovir was constructed and used to simulate the maternal and fetal exposure to tenofovir in virtual pregnant women population at different gestational weeks. Applying a similar approach to other drugs or chemicals may allow exposure prediction and risk assessment in the fetus following maternal administration of drugs or unintended exposure to environmental toxicants.
引用
收藏
页数:18
相关论文
共 72 条
[41]   Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Preexposure Prophylaxis [J].
Liu, Stephanie N. ;
Gufford, Brandon T. ;
Lu, Jessica Bo Li ;
Bushman, Lane R. ;
Anderson, Peter L. ;
Bergstrom, Richard F. ;
Desta, Zeruesenay ;
Gupta, Samir K. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (05) :1200-1208
[42]   A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4 [J].
Lu Gaohua ;
Abduljalil, Khaled ;
Jamei, Masoud ;
Johnson, Trevor N. ;
Rostami-Hodjegan, Amin .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 74 (05) :873-885
[43]   Rapid quantification of tenofovir in umbilical cord plasma and amniotic fluid in hepatitis B mono-infected pregnant women during labor by ultra-performance liquid chromatography/tandem mass spectrometry [J].
Ma, Zhiyuan ;
Li, Siying ;
He, Daqiang ;
Wang, Yuqing ;
Jiang, Huidi ;
Zhou, Hui ;
Jin, Jie ;
Lin, Nengming .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2020, 34 (09)
[44]   Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach [J].
Mathialagan, Sumathy ;
Piotrowski, Mary A. ;
Tess, David A. ;
Feng, Bo ;
Litchfield, John ;
Varma, Manthena V. .
DRUG METABOLISM AND DISPOSITION, 2017, 45 (04) :409-417
[45]   Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models [J].
Mendes, Mailys De Sousa ;
Hirt, Deborah ;
Vinot, Cecile ;
Valade, Elodie ;
Lui, Gabrielle ;
Pressiat, Claire ;
Bouazza, Naim ;
Foissac, Frantz ;
Blanche, Stephane ;
Le, Minh Patrick ;
Peytavin, Gilles ;
Treluyer, Jean-Marc ;
Urien, Saik ;
Benaboud, Sihem .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (04) :646-657
[46]   Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women [J].
Mendes, Mailys De Sousa ;
Hirt, Deborah ;
Urien, Saik ;
Valade, Elodie ;
Bouazza, Naim ;
Foissac, Frantz ;
Blanche, Stephane ;
Treluyer, Jean-Marc ;
Benaboud, Sihem .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (05) :1031-1041
[47]   Pharmacokinetics and Safety of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life [J].
Mirochnick, Mark ;
Taha, Taha ;
Kreitchmann, Regis ;
Nielsen-Saines, Karin ;
Kumwenda, Newton ;
Joao, Esau ;
Pinto, Jorge ;
Santos, Breno ;
Parsons, Teresa ;
Kearney, Brian ;
Emel, Lynda ;
Herron, Casey ;
Richardson, Paul ;
Hudelson, Sarah E. ;
Eshleman, Susan H. ;
George, Kathleen ;
Fowler, Mary G. ;
Sato, Paul ;
Mofenson, Lynne .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 (01) :33-41
[48]  
Moss DM, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00105-17, 10.1128/aac.00105-17]
[49]   The role of drug transporters in the kidney: lessons from tenofovir [J].
Moss, Darren M. ;
Neary, Megan ;
Owen, Andrew .
FRONTIERS IN PHARMACOLOGY, 2014, 5
[50]  
Neuhoff S, 2013, AAPS ADV PHARM SCI, V7, P150, DOI 10.1007/978-1-4614-8229-1_7